Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of KN026 in HER2+ Breast and Gastric Cancer
NCT03847168Phase 1Unknown
- Sponsor
- Alphamab Oncology
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anbenitamab in breast cancer, gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Alphamab Oncology. Primary endpoint: Proportion of patients experiencing dose limiting toxicities at 28 days. Status: unknown.
02
Drugs
anbenitamab
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03847168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847168.